Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1000394 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1000394 | EXPERIMENTAL | Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days). |
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1000394 (2.5mg) | DRUG | BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1) |
| BAY1000394 (5mg) | DRUG | BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2) |
| BAY1000394 | DRUG | BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule. |
Inclusion Criteria: * Japanese male or female subjects aged ≥20 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 * Life expectancy of at least 12 weeks * Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY1000394 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being evaluated in oncology clinical trials for patients with advanced malignancies. The drug is currently in Phase 1 clinical development.
BAY1000394 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational oncology drug.
BAY1000394 is in Phase 1 clinical development. Two Phase 1 trials have been completed, but no active trials are currently ongoing. The drug is investigational and has not been approved by regulatory authorities. It remains in early-stage clinical testing for the treatment of neoplasms.
BAY1000394 has been studied in two completed Phase 1 clinical trials. NCT01335256 evaluated safety and maximum tolerated dose in subjects with advanced malignancies in the United States. NCT02047890 was a Japanese monotherapy Phase I study. Both trials enrolled a total of 22 participants.
No alternative names for BAY1000394 have been disclosed in the clinical trial information. The drug is identified solely by its code name BAY1000394 in the registered clinical studies. It is an investigational small molecule being developed by Bayer AG for oncology indications.